Parkinson’s Disease
Parkinson’s Disease is a disorder of the central nervous system that affects movement, often including tremors.
Nerve cell damage in the brain causes dopamine levels to drop, leading to the symptoms of Parkinson’s.
Parkinson’s often starts with a tremor in one hand. Other symptoms are slow movement, stiffness, and loss of balance.
Medications can help control the symptoms of Parkinson’s.
Parkinson’s Disease is a progressive disease of the nervous system marked by tremor, muscular rigidity, and slow, imprecise movement, chiefly affecting middle-aged and elderly people. It is associated with degeneration of the basal ganglia of the brain and a deficiency of the neurotransmitter dopamine.
Symptoms:
Cluster Number:
Wiki Number: PW153
Diagnosis: Parkinson’s Disease (Very complex; please read the Wikipedia article.)
US Patients: 2-6X likelihood of dementia
World Patients: 6.2Mil&117,400 Deaths (2015)
Sex Ratio:
Age Onset: Over 60, usually; unless “early-onset Parkinson’s”
Brain Area: Cell deaths among the subantia nigra leads to dopamine deficits; Cells die from proteins into Lewy bodies in the neurons
Symptoms: tremor, slowness(bradykinesia), stiffness(excessive muscle contraction) and postural instability(10% fall weekly)
Progression: As it progresses, poor decision-making, less impulse control, impaired recall, less control of attention
Causes: genetics, injuries, pesticides;brain lesions from strokes;alpha-synuclein protein in the brain buildup; 50% have hallucinations
Medications: L-DOPA; deep brain stimulation by microelectrodes reduces muscular symptoms;
Therapies: Imaging by MRI, T2* and SW;, neuromelanin-MRI; Diffusion, MRI; PET; SPECT; DaTSCAN is the only FDA approved way to distinguish.
Youtube Video: Parkinson’s Disease: Adversity or Adventure?
Amazon or Library Book:
Parkinson’s Disease – Guide for the Newly Diagnosed
Click the book to link or buy from Amazon.
Support Group: parkinsons.org; 800-473-4636
(Parkinson’s Disease Foundation)
Support Group:michaeljfox.org; (Primarily designed to find a cure for Parkinson’s Disease. It may also have support groups.)
Contact your local Social Security office for possible Disability Benefits through their Disability Determination Services,
Section 12.02.
4 CURRENT ARTICLES
FROM PUBMED
The world-wide medical research
reports chosen for each diagnosis
Clicking each title opens the
PubMed article’s summary-abstract.
- Exploring a definition of healthy longevity in Chinese population based on Delphi methodby X Chai on May 8, 2024
Objective: To explore a definition of healthy longevity in the Chinese population based on the Delphi method. Methods: Through a comprehensive literature review and expert consultation, the dimensions in the definition of healthy longevity were identified, and a preliminary list of questions was created. Experts in clinical medicine, public health, basic research, and the elderly care service industry, who had been working in the field of geriatric health for at least 5 years, were invited to...
- Clinical value of video oculomotor evaluation in the differential diagnosis of multiple system atrophy and Parkinson's diseaseby Dongxiao Zhou on May 8, 2024
CONCLUSIONS: The combination of oculomotor parameters and clinical data may aid in the differential diagnosis of MSA and PD. Furthermore, VOE is vital in the identification of neurodegenerative diseases.
- Neuroimaging and plasma evidence of early white matter loss in Parkinson's disease with poor outcomesby Angeliki Zarkali on May 8, 2024
Parkinson's disease is a common and debilitating neurodegenerative disorder, with over half of patients progressing to postural instability, dementia or death within 10 years of diagnosis. However, the onset and rate of progression to poor outcomes is highly variable, underpinned by heterogeneity in underlying pathological processes. Quantitative and sensitive measures predicting poor outcomes will be critical for targeted treatment, but most studies to date have been limited to a single...
- Cerebellar Micro-RNA Profile in a Mouse Model of Spinocerebellar Ataxia Type 2by Sharan Paul on May 8, 2024
BACKGROUND AND OBJECTIVES: Micro-RNAs (miRNAs) are critical for regulating the expression of genes in multiple neurodegenerative diseases, but miRNAs have not been investigated in spinocerebellar ataxia type 2 (SCA2). SCA2, a dominantly inherited progressive neurodegenerative polyglutamine (polyQ) disease, is caused by a CAG repeat expansion in the ataxin-2 (ATXN2) gene. In this study, we determined miRNA transcriptomes in SCA2-BAC-ATXN2[Q72] transgenic mice.